AMRNAMARIN CORP PLC

Nasdaq www.amarincorp.com


$ 0.62 $ 0.01 (2.21 %)    

Friday, 23-Aug-2024 15:49:51 EDT
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 0.6286
$ 0.62 x 100
-- x --
-- - --
$ 0.57 - $ 1.37
495,354
na
0
$ 1.55
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 amarin-shares-latest-research-highlighting-vascepavazkepa-reduce-it-subgroup-data-and-new-mechanistic-insights-into-eicosapentaenoic-acid-to-be-presented-at-esc-congress-2024

Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® car...

 amarin-corp-q2-2024-adj-eps-001-beats-004-estimate-sales-67500m-beat-51019m-estimate

Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.04) b...

 hls-therapeutics-has-entered-into-a-product-listing-agreement-with-the-province-of-alberta-for-the-listing-and-public-reimbursement-of-amarins-vascepa-icosapent-ethyl-effective-august-1-2024

Under the terms of the PLA, Vascepa will be reimbursed as a Special Authority product by Alberta Health for the secondary preve...

 cantor-fitzgerald-reiterates-overweight-on-amarin-corp

Cantor Fitzgerald analyst Louise Chen reiterates Amarin Corp (NASDAQ:AMRN) with a Overweight.

 cantor-fitzgerald-reiterates-overweight-on-amarin-corp

Cantor Fitzgerald analyst Louise Chen reiterates Amarin Corp (NASDAQ:AMRN) with a Overweight.

 amarin-corp-q1-2024-adj-eps-001-beats-003-estimate-sales-56519m-miss-57045m-estimate

Amarin Corp (NASDAQ:AMRN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) b...

 amarin-highlights-key-data-providing-mechanistic-insights-into-eicosapentaenoic-acid-at-acc24

Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic activity o...

 amarin-announces-research-evaluating-benefits-of-vascepavazkepa-to-be-presented-at-the-american-college-of-cardiologys-annual-scientific-session--expo

-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the M...

 why-butterfly-network-shares-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...

 why-is-amarin-stock-trading-lower-after-q4-earnings

Amarin's Q4 2023 financials: Revenues at $74.71 million, beating consensus. US net product revenue is $64.9 million, down Y...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION